Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Exelead.

    Client Virtual Booth

    EXELEAD

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Exelead
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    6925 Guion Rd Indianapolis, IN 46268
    Telephone
    Telephone
    1-317-347-2800
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.exeleadbiopharma.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Definitive Agreement to Acquire Exelead will Strengthen Merck’s CDMO Offering for mRNA

    Details:

    Exelead specializes in complex injectable formulations, including Lipid Nanoparticle (LNP) based drug delivery technology which is key in mRNA-based vaccines for use in Covid-19 and many other indications.


    Lead Product(s): mRNA-based Vaccine

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Merck Group

    Deal Size: $780.0 million Upfront Cash: $780.0 million

    Deal Type: Acquisition January 06, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Exelead Inks deal to Manufacture Lipid Nanoparticles for Pfizer/bio N Tech Vaccine

    Details:

    Exelead, has delivered its first vaccine precursor batch manufactured at its facility, as part of an agreement with Pfizer for the Pfizer-BioNTech COVID-19 Vaccine, BNT162b2.


    Lead Product(s): Tozinameran

    Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162b2

    Highest Development Status: ApprovedProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Pfizer Inc

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration June 10, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search